Skip to main content
Qyuns Therapeutics Co., Ltd. logo

Qyuns Therapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 2509 ISIN · CNE1000069W9 HKEX Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2026-01-16 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 2509

About Qyuns Therapeutics Co., Ltd.

http://www.qyuns.net

Qyuns Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, industrialization, and commercialization of antibody drugs for autoimmune and allergic diseases. The company operates an integrated platform covering the entire value chain, from proprietary antibody discovery (including a rabbit antibody development platform) to cGMP-compliant, commercial-scale internal manufacturing. Qyuns focuses on improving drug accessibility and affordability in its target areas. Its robust pipeline features 10 drug candidates targeting major inflammatory pathways, such as IL-12/IL-23p40, IL-4R , IL-17A, IL-23p19, and TSLP. The pipeline addresses four key therapeutic areas: dermatology, rheumatology, respiratory, and digestive diseases, with several assets in late-stage clinical development.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of 45,000 shares by the issuer (Qyuns Therapeutics Co., Ltd.) on 16 January 2026. According to the provided definitions, a report of a company buying back its own shares is classified as 'Transaction in Own Shares' (POS).
2026-01-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of shares by the company (Qyuns Therapeutics Co., Ltd.) on the exchange, including the number of shares, price, and impact on treasury shares. This falls directly under the category of a company reporting the buyback of its own shares.
2026-01-15 English
VOLUNTARY ANNOUNCEMENT QX030N/CLD-423 ACHIEVED FIRST SUBJECTS DOSING IN PHASE I CLINICAL TRIAL CALDERA THERAPEUTICS SECURED CUMULATIVE FUNDING OF US$112.5 MILLION
Regulatory Filings Classification · 95% confidence The document is a 'Voluntary Announcement' issued by Qyuns Therapeutics Co., Ltd. regarding business developments, specifically the dosing of subjects in a clinical trial and funding updates for a partner company. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate announcement regarding business operations that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2026-01-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of the company's own shares (treasury shares) on the market. According to the provided definitions, a report of a company buying back its own shares is classified as 'Transaction in Own Shares' (POS).
2026-01-14 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of the company's own shares on the market, providing the number of shares, price, and aggregate cost. According to the filing definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-13 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of the company's own shares (treasury shares) on the market. According to the provided definitions, a report of a company buying back its own shares is classified as 'Transaction in Own Shares' (POS).
2026-01-12 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.